As biotech IPOs siz­zle on vir­tu­al Wall Street, 3 new play­ers roll the dice on meg­a­money gam­bles top­ping $325M

Back in ear­ly Jan­u­ary when I in­ter­viewed Gen­er­a­tion Bio CEO Ge­off Mc­Do­nough on his $110 mil­lion mega-raise, he was think­ing in terms of tak­ing an­oth­er 12 to 18 months to get in­to the clin­ic and then fil­ing an IPO. They were, af­ter all, still pre­clin­i­cal af­ter 4 years in the lab.

But with in­vestors still clear­ly fo­cused on biotech dur­ing the pan­dem­ic, a lot of things are go­ing faster now. In­clud­ing IPO­ing, which is siz­zling for the right com­pa­nies.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.